bioRxivNeurosciencePreprint
The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics
James R. EvansiD, Emil Karl GustavssoniD, Ivan DoykoviD, David P. MurphyiD, Gurvir S. VirdiiD, Joanne LachicaiD, Alexander RöntgeniD, Mhd Hussein MurtadaiD, Chun Wei PangiD, Hannah L. MacphersoniD, Anna I. WernickiD, Christina E. ToomeyiD, Dilan S. AthaudaiD, Minee L. ChoiiD, John HardyiD, Nicholas W. WoodiD, Michele VendruscoloiD, Kevin A. MillsiD, Wendy HeywoodiD, Mina RyteniD, Sonia GandhiiD
Abstract
The role of the SNCA gene locus in driving Parkinsons disease (PD) through rare and common genetic variation is well-recognized, but the transcriptional diversity of SNCA in vulnerable cell types remains unclear. We performed SNCA long-read RNA sequencing in human dopaminergic neurons and show that annotated SNCA transcripts account for only 5% of expression. Rather, the majority of expression (75%) at the SNCA locus originates from transcripts with alternative 5 and 3 untranslated regions. Importantly, 10% originates from transcripts encoding open reading frames not previously annotated, which are translated and detectable in human postmortem brain. Defining the 3 untranslated regions enabled the rational design of antisense oligonucleotides targeting the majority of SNCA transcripts, leading to the effective reversal of PD pathology, including protein aggregation, mitochondrial dysfunction, and toxicity. Resolving the complexity of the SNCA transcriptional landscape impacts RNA therapies and highlights differences in protein isoforms and their contribution to disease.
- organism: human
- assay: long-read sequencing
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: statistical model
- approach: experimental assay
- Citations
- 9
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Tracy A. Cole, Hien Tran Zhao, … Katrina L. Paumier·bioRxiv·Nov 4, 2019
- The landscape of SNCA transcripts across synucleinopathies: New insights from long reads sequencing analysis
Elizabeth Tseng, William J. Rowell, … Ornit Chiba‐Falek·Frontiers in GeneticsPeer-reviewed·Jul 9, 2019
- Neuronal titration of Snca via enhancer disruption mitigates disease onset in a Parkinson's disease mouse model
Rachel J. Boyd, A Ra Kho, … Andrew S. McCallion·BrainPeer-reviewed·Jan 6, 2026
- Neuronal SNCA transcription during Lewy body formation
T. Kon, S. L. Forrest, … G. G. Kovacs·bioRxiv·Aug 19, 2023
- Oligodendroglia vulnerability in the human dorsal striatum in Parkinson's disease
Juan M. Barba-Reyes, Lisbeth Harder, … Ana B. Muñoz‐Manchado·Acta NeuropathologicaPeer-reviewed·May 5, 2025
- Single cell transcriptomics reveals enrichment of aggregation-prone alpha-synuclein isoforms across synucleinopathies
Elliot Keats Shwab, Webb Pierson, … Ornit Chiba‐Falek·bioRxiv·Oct 13, 2025